Prophylactic Human Vaccine Market Size 2020 with CAGR Value, Top Countries Data, Challenges, Business Opportunities

Prophylactic human vaccines stimulate the immune response and are intended for ameliorating the effects of future infection caused by pathogens in human beings. Novel vaccine development technologies such as viral-like particles are used in developing Hepatitis B Virus (HBV) vaccines, and Human Papilloma Virus (HPV) vaccines. For instance, in March 2014, CureVac AG received EUR 2 million Vaccine Prize from European Commission for its novel RNActive vaccine technology. This RNActive vaccine technology enables production of safe, efficacious, and cost-effective vaccines that are protected against elevated temperature as well as inadvertent freezing.

Request Sample Copy of this Report @

Increasing number of pipeline studies and rising involvement of key players for vaccine development is expected to propel growth of the prophylactic human vaccine market during the forecast period. For instance, in October 2018, CureVac AG, announced to initiate dose escalation phase I clinical trial for CV7202 mRNA-based rabies vaccine. CV7202 is a prophylactic vaccine encoding RABV-G, the rabies virus glycoprotein. This will enable vaccinated individual’s own cells to produce RABV-G protein, by which immune response gets triggered. This study is estimated to complete in January 2021.

Moreover, in October 2018, Valneva SE announced progress in its Phase 1 program targeting a single-shot vaccine against Chikungunya. It is designed for prophylactic, active, single-dose immunization against Chikungunya in humans. The vaccine aims for long-lasting protection and an anticipated safety profile similar to other approved vaccines for active immunization in adults and children.

The market can be segmented into:

By Vaccine Technology

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Polysaccharide Vaccines
  • Conjugate Vaccines
  • Recombinant Vaccines

The key players operating in prophylactic human vaccine market include, GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc., Altimmune, Inc., Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, Shanghai BravoBio Co., Ltd., SK Chemicals Co., Ltd., Takeda Pharmaceutical Company Limited, BiondVax Pharmaceuticals Ltd., and SK Chemicals Co., Ltd.

Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount for Buyers UPTO 30% OFF On Any Research Report

Buy Now with Discount for Premium Report :

The chapters covered in the research report are as follows:

Chapter 1, 2: Targets of the Global Prophylactic Human Vaccine Market, encompassing market introduction, product images, market summary, and development scope.

Chapter 3, Chapter 4: Global Market Competition, Sales Volume, and Market Profit by Manufacturer.

Chapters 5, 6, 7: Global Supply (Production), Consumption, Exports, Imports by Regions such as USA, Asia Pacific, China, India, Japan. From 2015 to 2024, we conduct regional market research based on regional sales rate and market share.

Chapters 8, 9, 10: Global Market Analysis by Application, Cost Analysis, Marketing Strategy Analysis, Distributor/Trader

Chapters 11, 12: Market Information and Research Conclusions, Appendix and Data Sources.

The market report also primarily identifies additional useful and useful information about the industry, including the Prophylactic Human Vaccine market development trends analysis, return on investment, and feasibility analysis. Additionally, SWOT analysis is distributed in the report to analyze the growth of key global market players in the Prophylactic Human Vaccine market industry.

In addition, the research report investigates:

Competitors and manufacturers in the global market

By product type, application and growth factor

Industry status and outlook for major applications / end users / usage areas

Request For PDF Brochure @

Thanks for reading this article. You can also get individual chapter sections, such as North America, Europe, or Asia, or regional versions of the report.

Contact us:

Mr. Shah
Senior Client Partner – Business Development

Back to top button